Abbvie Inc.

Fisons Ltd.

Abbott Laboratories Corporation

Pennwalt Corporation

Advanced Global Equities and Intellectual Properties, Inc.

Other

Astra Ab

Abbvie Bahamas Limited

James J Napier

Ronald C Griffith

Ted Stewart

Shuang Chen

Albert Wayne Kruger

Jean-Christophe C Califano

Edwin O Lundell

Su Yu

Michael A Staeger

Steven Cramer Cullen

Kenneth W Funk

Jane L Chang

Robert B Miller

Vimal Kishore

Calvin L Becker

Anthony Ralph Haight

Geoff G Z Zhang

Howard E Morton

Yi-Yin Ku

Steven J Wittenberger

Jien-Heh J Tien

Steven A King

Russell Drew Cink

Daniel J Plata

David A Riley

David R Hill

James Russell Matz

Paul J Brackemeyer

Marvin Robert Leanna

Michael Rasmussen

Eric J Stoner

Margaret Chi-Ping Hsu

Arthur J Cooper

Maureen Ann McLaughlin

Elaine C Lee

Tim Grieme

Prasad S Raje

Matthew John Peterson

Mahendra N Deshpande

Mark R Holst

Bhi-Yung Cheng

David Riley

Matthew J Peterson

Marvin R Leanna

Maureen A Mclaughlin

This invention is directed to: (a) processes for preparing a compound and salts thereof that, inter alia, are useful for inhibiting hepatitis C virus (HCV); (b) intermediates useful for the preparation of the compound and salts; (c) pharmaceutical compositions comprising the compound or salts; and (d) methods of use of such compositions.

Process for preparing antiviral compound

The invention relates to a crystalline monohydrate of (4s)-4-(5-phenyl-1,3,4-thiadiazol-2-yloxy)-1-azatricyclo[3.3.1.1]decane dihydrogen citrate, compositions comprising such compound, and a process for preparing such compound.

Monohydrate of azaadamantane derivatives

A compound, (4s)-1-azaadamantane-4yl formate ester, is described. In addition, a process is described for preparing (4s)-1-azaadamantane-4yl formate ester, aminothiadiazole-phenyl phosphate salt, bromothiadizole-phenyl or (4s)-4-(5-phenyl-1,3,4-thiadiazol-2-yloxy)-1-azatricyclo[3.3.1.1]-decane dihydrogen citrate. Furthermore, a process is described, comprising step of hydrolyzing (4s)-1-azaadamantane-4yl formate ester to form (4s)-1-azaadamantan-4-ol HBr salt.

Azaadamantane formate ester and process for preparing azaadamantane derivatives

Disclosed is a fuel injection mechanism having a horizontal control surface formed within a plunger for regulating the start of fuel injection. The horizontal control surfaces are formed within one or more of the two opposed ridges formed within the plunger defining a recessed channel there between. The horizontal control surfaces of the ridges regulate the opening and closing of the ports formed within the bushing of the injector. The horizontal control surfaces contribute to reduced wear and provide for accurate timing and fuel quantity delivery.

Horizontal control surface for a fuel injector

Disclosed is an electronic module designed to use the locomotive engine's speed sensors to detect such changes in engine speed (rpm), as required by the locomotive operator moving the throttle notch handle. Once a speed change is detected, the module commands an air valve on each of the locomotive's main air reservoir tanks, (designed to handle the normal operating main reservoir air pressure), to open and allow them to discharge into the engine's intake manifolds located on both sides of the diesel engine.

Air pressure boost assist

Disclosed is an apparatus and method for lubricating a plunger residing within a bushing of a fuel injector. The apparatus includes a fuel lubrication mechanism comprised of lubrication grooves formed within and around the outer axial surfaces of the plunger. The grooves act as fuel reservoirs for storing a small portion of fuel on the outer axial surface of the plunger. The stored or retained fuel interfaces with the walls of the bushing during injection to provide a lubricated interface between the bushing and plunger. The lubricated interface increases the service life of the fuel injector by reducing seizing, scoring and scuffing caused by excessive heat.

Fuel injection lubrication mechanism for continuous self lubrication of a fuel injector

Disclosed is a fuel injection nozzle assembly comprising a poppet type valve assembly capable of producing a circumferential spray pattern. The fuel injection nozzle assembly includes a nozzle body defining a valve outlet into which is fitted a needle valve having a flanged portion extending from the nozzle body. The flanged portion opens and closes the valve outlet as the needle valve travels up and down the nozzle body as dictated by the fuel pressure within the nozzle body. The flanged portion may further direct the fuel spray into a combustion chamber.

Fuel injector nozzle assembly

In one aspect, the invention relates to a process for preparing 6-O-substituted erythromycin derivatives comprising reacting 2&prime;-substituted and optionally 4&Prime;-substituted 9-oxime erythromycin derivatives with an alkylating agent in the presence of a palladium catalyst and phosphine. In another aspect, the invention relates to processes for preparing 6-O-substituted erythromycin ketolides using the palladium-catalyzed alkylation reaction.

Process for preparing 6-o-substituted erythromycin derivatives

A method is provided for preparing decapeptide and undecapeptide derivatives of LHRH by solution phase peptide chemistry as well as intermediate peptides useful in the same method.

Process and intermediates for the synthesis of LHRH antagonists

Process for intermediates for the synthesis of LHRH antagonists

There is provided a method of treatment of neurological disorders, such as epilepsy, stroke and cerebral ischaemia, which comprises the administration of a compound of Formula I: ##STR1## wherein, Ar.sub.1 and Ar.sub.2, which may be the same or different, independently represent phenyl or phenyl substituted by one or more of amino, nitro, halogen, hydroxy, C1 to 6 alkoxy, C1 to 6 alkyl or cyano; R.sub.1 represents hydrogen, C1 to 6 alkyl, C1 to 6 alkoxycarbonyl; R.sub.2 represents hydrogen or COCH.sub.2 NH.sub.2 ; R.sub.3 represents hydrogen or C1 to 6 alkyl; in addition, when R.sub.2 represents hydrogen either one or both of Ar.sub.1 and Ar.sub.2 may also represent 2-, 3- or 4-pyridinyl and R.sub.1 may also represent trihalomethyl; or a pharmaceutically acceptable salt thereof. Some of the compounds of formula I are novel, and these are also provided, together with pharmaceutical compositions containing the novel compounds.

Arylalkyl-amines having anticonvulsant and neuroprotective properties

There is provided a method of treatment of neurological disorders, such as epilepsy, stroke and cerebral ischaemia, which comprises the administration of a compound of Formula I: ##STR1## wherein, Ar.sub.1 and Ar.sub.2, which may be the same or different, independently represent phenyl or phenyl substituted by one or more of amino, nitro, halogen, hydroxy, C1 to 6 alkoxy, C1 to 6 alkyl or cyano;

Spiro[cycloalkylbenzene-1,1'-(1',2',3',4'-tetrahydro-isoquinolines)]

Growing community of inventors

Lindenhurst, IL, United States of America

James J Napier